AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

AstraZeneca share price held steady this week after the company published strong financial results on Tuesday.

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer ...

AstraZeneca’s revenues beat expectations for the second quarter, powered by record growth in its all-important US business.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca adjusts its U.S. strategy by proposing drug price cuts and expanding local production in response to pressure ...

For the FTSE 100 it was a day where things only got better as the day went on, with the bluechip benchmark closing at yet ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...